Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Can-Fite Biopharma Ltd ADR (NY: CANF ) 2.530 -0.070 (-2.69%) Official Closing Price Updated: 8:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Can-Fite Biopharma Ltd ADR < Previous 1 2 3 Next > Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session June 30, 2022 Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical... Via Benzinga Aspen Aerogels And 28 Stocks Moving Premarket June 30, 2022 Gainers Via Benzinga Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial June 29, 2022 Via Benzinga Can Fite Biofarma: Q1 Earnings Insights May 26, 2022 Can Fite Biofarma (AMEX:CANF) reported its Q1 earnings results on Thursday, May 26, 2022. Here's what investors need to know about the announcement. Via Benzinga This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday June 30, 2022 Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering. Via Benzinga The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data June 29, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga CAN-FITE ISSUES LETTER TO SHAREHOLDERS January 05, 2022 Q1 2022: Psoriasis Phase III Data & Commencement of Enrollment in Phase IIb NASH H1 2022: Commencement of Enrollment in Phase III Liver Cancer PETACH TIKVA,... Via Benzinga Can-Fite Q1 Revenue Increases 38.5%, Phase III Psoriasis Treatment Study Results Expected In Q2 May 26, 2022 Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) released financial results for the quarter ended March 31, 2022, revealing revenue of $200,000, an increase of or 38.5%, compared to $150,000 in Q1... Via Benzinga Attacking Diseases On Multiple Fronts — Pharmaceutical Development Combined With Cannabis? April 12, 2022 Picture credit: Esteban Lopez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Via Benzinga Can-Fite Reports Revenue Growth In 2021, Provides Clinical Update March 24, 2022 Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI) announced Via Benzinga This Biotech Company Looks To Be Targeting A New Drug To Treat NASH, The Leading Cause of Liver Transplants March 24, 2022 This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Via Benzinga Can-Fite To Reveal Findings In Treatment Of Liver Cancer And Fibrosis With Cannabinoids At CannX March 11, 2022 Dr. Pnina Fishman CEO of Can-Fite BioPharma Ltd. (AMEX:CANF)... Via Benzinga Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study March 08, 2022 Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson... Via Benzinga Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor? February 03, 2022 Photo by Diana Polekhina on Unsplash Via Benzinga A New Oral Therapy for Psoriasis Could Be Coming Soon January 24, 2022 Photo by Towfiqu barbhuiya on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice... Via Benzinga Can Fite's Piclidenoson Destroys Pathological Skin Cells, Lab Study Shows January 13, 2022 Can-Fite BioPharma Ltd (NYSE: CANF) announced preclinical studies with skin cells, modeling psoriasis in humans, showing that Piclidenoson destroys pathological skin... Via Benzinga The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact January 13, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... Via Benzinga PRIOR TO PHASE III PSORIASIS DATA RELEASE CAN FITE REPORTS THAT PICLIDENOSON DESTROYS PATHOLOGICAL SKIN CELLS IN VITRO January 13, 2022 Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American:... Via Benzinga Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference January 10, 2022 PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs... Via Benzinga FOLLOWING COMPLETE CLEARANCE OF CANCER LESIONS IN ADVANCED LIVER CANCER PATIENT, CAN-FITE IS FILING PATENT APPLICATIONS FOR THE TREATMENT OF VARIOUS ADVANCED SOLID TUMORS January 03, 2022 Namodenoson Headed into Pivotal Phase III Liver Cancer Study PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a... Via Benzinga 45 Biggest Movers From Yesterday December 30, 2021 Gainers Puxin Limited (NYSE: NEW) shares surged 80% to close at $0.54 on Wednesday after reporting results for the second quarter. United Time Technology Co., Ltd. (NASDAQ: UTME... Via Benzinga 26 Stocks Moving In Wednesday's Mid-Day Session December 29, 2021 Gainers Puxin Limited (NYSE: NEW) jumped 100.5% to $0.6016 after reporting results for the second quarter. ShiftPixy, Inc. (NASDAQ: PIXY) climbed 38.4% to $1.55 after surging 43... Via Benzinga CANF Stock: The Cancer-Fighting News Sending Can-Fite Higher Today December 29, 2021 Can-Fite BioPharma is rising on Wednesday following positive Phase 2 data on its liver cancer treatment. Can it help turn CANF stock around? Via InvestorPlace 38 Stocks Moving In Tuesday's Mid-Day Session December 21, 2021 Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining... Via Benzinga 55 Biggest Movers From Yesterday December 22, 2021 Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday December 21, 2021 Good morning, trader! We're kicking off the day with a dive into some of the biggest pre-market stock movers for Tuesday! Via InvestorPlace 26 Stocks Moving in Tuesday's Pre-Market Session December 21, 2021 Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains... Via Benzinga 65 Biggest Movers From Yesterday December 21, 2021 Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... Via Benzinga Mid-Afternoon Market Update: Dow Tumbles 500 Points; Bluerock Residential Growth Shares Spike Higher December 20, 2021 Toward the end of trading Monday, the Dow traded down 1.42% to 34,862.49 while the NASDAQ fell 1.38% to 14,960.51. The S&P also fell, dropping 1.34% to 4,558.87. The U.S. has... Via Benzinga Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient December 20, 2021 Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson... Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.